Trial Profile
A Phase II Study of Perioperative mFOLFOX6 Chemotherapy Plus Pembrolizumab(MK-3475) Combination in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Sep 2017 Planned number of patients changed from 40 to 0.
- 25 Sep 2017 Status changed to withdrawn.
- 27 Oct 2016 New trial record